Poseida Therapeutics, Inc.

NasdaqGS:PSTX Stock Report

Market Cap: US$306.4m

Poseida Therapeutics Dividend

Dividend criteria checks 0/6

Poseida Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.8%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.12
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PSTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSTX's dividend payments have been increasing.


Dividend Yield vs Market

Poseida Therapeutics Dividend Yield vs Market
How does PSTX dividend yield compare to the market?
SegmentDividend Yield
Company (PSTX)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (PSTX)0%

Notable Dividend: Unable to evaluate PSTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PSTX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTX has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.